Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–12 of 12 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: maralixibat Clear all

Conditions: Healthy Volunteers
Interventions: Placebo, Maralixibat, Volixibat; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Alagille Syndrome
Interventions: maralixibat; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 12 Months and older
U.S. locations: 14
States / cities: Los Angeles, California • Redwood City, California • San Francisco, California + 11 more

Conditions: Alagille Syndrome
Interventions: LUM001 (Maralixibat); Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more

Conditions: Progressive Familial Intrahepatic Cholestasis (PFIC)
Interventions: Maralixibat; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 10
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more

Conditions: Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Interventions: Maralixibat, Placebo; Drug · Other
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Los Angeles, California • Palo Alto, California • Chicago, Illinois + 4 more

Conditions: Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis
Interventions: Livmarli; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 5 more

Conditions: Biliary Atresia
Interventions: Maralixibat, Placebo; Drug · Other
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 21 Days to 111 Days
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 7
States / cities: Phoenix, Arizona • Atlanta, Georgia • New York, New York + 3 more

Conditions: Progressive Familial Intrahepatic Cholestasis (PFIC)
Interventions: Maralixibat, Placebo; Drug · Other
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 11
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 8 more

Conditions: Cholestatic Liver Disease
Interventions: Maralixibat; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 12 Months and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 6
States / cities: Los Angeles, California • Indianapolis, Indiana • Philadelphia, Pennsylvania + 3 more

Conditions: Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Cholestatic Liver Disease
Interventions: Maralixibat; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 0 Days to 364 Days
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more

Conditions: Constipation Chronic Idiopathic, Cystic Fibrosis
Interventions: Maralixibat 9.5 MG/ML [Livmarli]; Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 1 Year to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Progressive Familial Intrahepatic Cholestasis (PFIC)
Interventions: LUM001 (Maralixibat); Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 12 Months to 18 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 5
States / cities: Los Angeles, California • Aurora, Colorado • Cincinnati, Ohio + 2 more

Search by objective public record fields.

Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion

A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)

An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome

An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)

Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)

Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai

A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)

MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study

A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

Maralixibat in Patients With Cystic Fibrosis and Constipation

Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis